Skip to content

Contact +44 (0) 20 7060 7474 email us

Biotechnology

Global Drug Eluting Balloons (DEB)

Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

Publication Date April 2010
Publisher Global Data
Product Type Report
Pages 56
ISBN Number not applicable
Product Code GDA01047

Price

£2,275.00
approximately: $3,502 | €2,750

PDF

Buy Now

Order above formats by FAX

Order by Fax

Ask a question about this product »

Summary

GlobalData's report, 'Global Drug Eluting Balloons (DEB) Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016' provides key data, information and analysis on the global drug eluting balloons (DEB) market, a key segment within the medical device industyr. The report provides market landscape, competitive landscape and market trends information the drug eluting balloons (DEB) market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings. Drug Eluting Balloons (DEB) have recently come into the limelight following the Conformité Européenne (CE) approval of several DEB products and their consequent launch in Europe. The recently concluded clinical trials in Europe have produced superior results to the current interventions for a large number of indications such as in-stent restenosis, peripheral vascular disease and bifurcation lesions. The global drug eluting balloons (DEBs) market was valued at $60m in 2009 and is expected to be driven by increased adoption by physicians as long term clinical data is released, and as the device is adopted for newer indications such as peripheral vascular disease.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope:

  • Key geographies covered include the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
  • Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2009.
  • Qualitative analysis of key market trends, market drivers, and restraints by each category within the drug eluting balloons (DEB) market.
  • The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
  • Key players covered include Aachen Resonance, B. Braun, Bayer, Caliber Therapeutics, Cook Medical, Eurocor, Invatec and Lutonix.

Reasons to buy:

  • Develop business strategies by understanding the trends and developments that are driving the drug eluting balloons (DEB) market globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Identify key players best positioned to take advantage of the emerging market opportunities.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • What's the next being thing in the drug eluting balloons (DEB) market landscape? - Identify, understand and capitalize.
  • Make more informed business decisions from the insightful and in-depth analysis of the global drug eluting balloons (DEB) market and the factors shaping it.

Contents

  • 1 Table of contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction and Overview
    • 2.1 GlobalData Report Guidance
  • 3 Major Cardiovascular Indications Approved for Drug Eluting Balloons (DEB): Disease Pathophysiology, Etiology, and Epidemiology
    • 3.1 In-stent Restenosis
      • 3.1.1 Introduction
      • 3.1.2 Pathophysiology
      • 3.1.3 Etiology: Risk Factors for the Disease
    • 3.2 In-Stent Restenosis Epidemiology: Global
      • 3.2.1 Treatment Flow Model
    • 3.3 In-stent Restenosis: Device Based Treatment Modalities and their Outcomes
    • 3.4 Peripheral Vascular Disease: Overview and Pathophysiology
      • 3.4.1 Introduction
    • 3.5 Peripheral Vascular Disease Epidemiology: Global
      • 3.5.1 Treatment Flow Model
    • 3.6 Peripheral Vascular Disease: Device Based Treatment Modalities and their Outcomes
  • 4 Global Drug Eluting Balloons Market : Market Characterization
    • 4.1 Global Drug Eluting Balloons Market, Revenue ($m), 2007-2016
    • 4.2 Global Drug Eluting Balloons Market, Volume (Units), 2007-2016
    • 4.3 Drug Eluting Balloons, Market Dynamics
      • 4.3.1 Market Drivers
      • 4.3.2 Market Restraints
    • 4.4 Drug Eluting Balloons: Unmet Need and Opportunities
      • 4.4.1 Unmet Need
      • 4.4.2 Opportunities
  • 5 Global Drug Eluting Balloons (DEB) Market: Cross-Country Market Analysis and Forecasts
    • 5.1 Global Drug Eluting Balloons Market: Cross-Country Analysis
    • 5.2 Drug Eluting Balloons (DEB), Revenue, By Country, 2007 - 2016
      • 5.2.1 Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 - 2016
      • 5.2.2 Drug Eluting Balloons Market, France, Revenue ($m), 2007 - 2016
      • 5.2.3 Drug Eluting Balloons Market, UK, Revenue ($m), 2007 - 2016
      • 5.2.4 Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 - 2016
      • 5.2.5 Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 - 2016
      • 5.2.6 Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 - 2016
      • 5.2.7 Drug Eluting Balloons Market, India, Revenue ($m), 2009 - 2016
      • 5.2.8 China Drug Eluting Balloons Market, Revenue ($m), 2009 - 2016
  • 6 Global Drug Eluting Balloons Market: Company Share Analysis and Key Market Participants
    • 6.1 Global Drug Eluting Balloons Market, Company Share (%), 2009
    • 6.2 B Braun
      • 6.2.1 Overview
      • 6.2.2 Drug Eluting Balloons Portfolio
    • 6.3 Eurocor
      • 6.3.1 Overview
    • 6.4 Invatec
      • 6.4.1 Overview
      • 6.4.2 Drug Eluting Balloons Portfolio
    • 6.5 Aachen Resonance GmbH
      • 6.5.1 Overview
      • 6.5.2 Drug Eluting Balloons Portfolio
  • 7 Global Drug Eluting Balloons Market: Key Marketed Products
    • 7.1 SeQuent Please
      • 7.1.1 Product Overview and Description
      • 7.1.2 Key Technology
      • 7.1.3 Clinical Study Results
    • 7.2 DIOR Paclitaxel-Eluting Coronary Balloon Catheter
      • 7.2.1 Product Overview and Description
      • 7.2.2 Key Technology
      • 7.2.3 Clinical Study Results
    • 7.3 Elutax
      • 7.3.1 Product Overview and Description
      • 7.3.2 Key Technology
      • 7.3.3 Clinical Study Results
    • 7.4 IN.PACT Amphirion Paclitaxel Eluting Balloon Catheter
      • 7.4.1 Product Description
      • 7.4.2 Key Technology
      • 7.4.3 Clinical Study Results
  • 8 Global Drug Eluting Balloons Market: Strategic Pipeline Assessment
    • 8.1 Pipeline Technology Assessment
      • 8.1.1 Pipeline Technology Assessment for Drug Eluting Balloons by Development Stage
      • 8.1.2 Pipeline Technology Assessment for Drug Eluting Balloons by Unmet Need
      • 8.1.3 Novel Pipeline Technology Assessment for Drug Eluting Balloons
    • 8.2 Drug Eluting Balloons: List of Pipeline Products
    • 8.3 Profiles of Promising Products under Clinical Development
      • 8.3.1 Lutonix
      • 8.3.2 Advance 18PTX
      • 8.3.3 Cotavance
      • 8.3.4 Genesis DESA Catheter
      • 8.3.5 Drug-Eluting PTA Balloon Catheter
      • 8.3.6 Drug-Eluting Balloon
      • 8.3.7 PTCA Balloon Genistein-coated balloon catheter
  • 9 Global Drug Eluting Balloons Market: Strategic Deals Analysis
    • 9.1 Key Acquisitions
      • 9.1.1 Medtronic Acquired Invatec
      • 9.1.2 MEDRAD Completes Acquisition Of Possis Medical
      • 9.1.3 Opto Circuits Acquired Eurocor
    • 9.2 Key Partnerships
      • 9.2.1 Maxcor entered a strategic agreement with Micell Technologies to develop new balloon and stent system
      • 9.2.2 Eurocor enters distribution agreement with Goodman for entering Japan market in 2007
      • 9.2.3 MEDRAD Enters Into Licensing Agreement With B. Braun Melsungen
      • 9.2.4 DSM Biomedical and Caliber Therapeutics form partnership to develop a drug-delivery balloon catheter to treat atherosclerosis
      • 9.2.5 Aachen Resonance enters into a distribution agreement with Biotronik to distribute Elutax in Europe
  • 10 Appendix
    • 10.1 Definitions
      • 10.1.1 Interventional Cardiology
      • 10.1.2 Peripheral Vascular Devices
      • 10.1.3 Drug Eluting Balloons
    • 10.2 Acronyms
    • 10.3 Research Methodology
    • 10.4 Secondary Research
    • 10.5 Primary Research
    • 10.6 Models
    • 10.7 Forecasts
    • 10.8 Expert Panels
    • 10.9 GlobalData Consulting
    • 10.10 Contact Us
    • 10.11 Disclaimer
  • List of Tables
    • Table 1: Drug Eluting Balloons Market, Global, Revenue($m), 2007-2016
    • Table 2: Drug Eluting Balloons Market, Global, Volume (Units), 2007 - 2016
    • Table 3: Drug Eluting Balloons Market, Global, Revenue and Growth Comparison
    • Table 4: Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 - 2016
    • Table 5: Drug Eluting Balloons Market, France, Revenue ($m), 2007 - 2016
    • Table 6: Drug Eluting Balloons Market, UK, Revenue ($m), 2007 - 2016
    • Table 7: Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 - 2016
    • Table 8: Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 - 2016
    • Table 9: Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 - 2016
    • Table 10: Drug Eluting Balloons Market, India, Revenue ($m), 2009 - 2016
    • Table 11: Drug Eluting Balloons Market, China, Revenue ($m), 2009 - 2016
    • Table 12: Drug Eluting Balloons Market, Global, Key Company Shares (%), 2009
    • Table 13: B Braun, Drug Eluting Balloons, Pipeline Products
    • Table 14: Eurocor, Drug Eluting Balloons, Pipeline Products
    • Table 15: Invatec, Drug Eluting Balloons, Pipeline Products
    • Table 16: Aachen Resonance, Drug Eluting Balloons, Pipeline Products
    • Table 17: List of Pipeline Products, Drug Eluting Balloons
    • Table 18: Lutonix Balloon angioplasty catheter - A Prospective, Multicenter, European Registry Investigating The Lutonix Paclitaxel-Coated Balloon For The Treatment Of In-Stent Restenosis Within Bare-Metal Stents
    • Table 19: Lutonix Balloon angioplasty catheter - An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions
    • Table 20: Lutonix Balloon angioplasty catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Catheter vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries With and Without Stenting
    • Table 21: Advance 18 PTX Balloon Catheter - Advance 18PTX Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery With a Paclitaxel-coated Balloon
  • List of Figures
    • Figure 1: Treatment Flow Model, Drug Eluting Balloons for Treatment of In-stent restenosis, 2009
    • Figure 2: Device Based Treatment Modalities for In-Stent Restenosis
    • Figure 3: Treatment Flow Model, Drug Eluting Balloons for Treatment of Peripheral Artery Disease, 2009
    • Figure 4: Device Based Treatment Modalities for Peripheral Vascular Disease
    • Figure 5: Drug Eluting Balloons Market, Global, Revenue ($m), 2007-2016
    • Figure 6: Drug Eluting Balloons Market, Global, Volume (Units), 2007 - 2016
    • Figure 7: Unmet Need and Opportunities Analysis for Drug Eluting Balloons
    • Figure 8: Drug Eluting Balloons Market, Global, Revenue and Growth Comparison
    • Figure 9: Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 - 2016
    • Figure 10: Drug Eluting Balloons Market, France, Revenue ($m) , 2007 - 2016
    • Figure 11: Drug Eluting Balloons Market, UK, Revenue ($m), 2007 - 2016
    • Figure 12: Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 - 2016
    • Figure 13: Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 - 2016
    • Figure 14: Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 - 2016
    • Figure 15: Drug Eluting Balloons Market, India, Revenue ($m), 2009 - 2016
    • Figure 16: Drug Eluting Balloons Market, China, Revenue ($m), 2009 - 2016
    • Figure 17: Drug Eluting Balloons Market, Global, Company Share (%), 2009
    • Figure 18: Pipeline Technology Assessment for Drug Eluting Balloons By Development Stage, Europe
    • Figure 19: Pipeline Technology Assessment for Drug Eluting Balloons By Development Stage, US
    • Figure 20: Pipeline Technology Assessment for Drug Eluting Balloons by Unmet Need
    • Figure 21: Novel Pipeline Technology Assessment for Drug Eluting Balloons
    • Figure 22: GlobalData Methodology